Cynthia M Rand1, Hollyce Tyrrell2, Rachel Wallace-Brodeur3, Nicolas P N Goldstein4, Paul M Darden5, Sharon G Humiston6, Christina S Albertin7, William Stratbucker8, Stanley J Schaffer4, Wendy Davis3, Peter G Szilagyi9. 1. Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY. Electronic address: cynthia_rand@urmc.rochester.edu. 2. Academic Pediatrics Association, McLean, Va. 3. National Improvement Partnership Network, University of Vermont Medical Center, Burlington, Vt. 4. Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY. 5. Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Okla. 6. Department of Pediatrics, University of Missouri Kansas City School of Medicine and Children's Mercy Kansa City, Kansas City, Mo. 7. Albertin Health Services Research, Indianapolis, Ind. 8. Department of Pediatrics, Michigan State University/Helen DeVos Children's Hospital, Grand Rapids, Mich. 9. Department of Pediatrics, Mattel Children's Hospital, University of California at Los Angeles, Los Angeles, Calif.
Abstract
OBJECTIVE: Human papillomavirus (HPV) vaccination rates remain low, in part because of missed opportunities (MOs) for vaccination. We used a learning collaborative quality improvement (QI) model to assess the effect of a multicomponent intervention on reducing MOs. METHODS: Study design: pre-post using a QI intervention in 33 community practices and 14 pediatric continuity clinics over 9 months to reduce MOs for HPV vaccination at all visit types. MEASURES: outcome measures comprised baseline and postproject measures of 1) MOs (primary outcome), and 2) HPV vaccine initiation and completion. Process measures comprised monthly chart audits of MOs for HPV vaccination for performance feedback, monthly Plan-Do-Study-Act surveys and pre-post surveys about office systems. INTERVENTION: providers were trained at the start of the project on offering a strong recommendation for HPV vaccination. Practices implemented provider prompts and/or standing orders and/or reminder/recall if desired, and were provided monthly feedback on MOs to assess their progress. ANALYSES: chi-square tests were used to assess changes in office practices, and logistic regression used to assess changes in MOs according to visit type and overall, as well as HPV vaccine initiation and completion. RESULTS: MOs overall decreased (from 73% to 53% in community practices and 62% to 55% in continuity clinics; P < .01, and P = .03, respectively). HPV vaccine initiation increased for both genders in community practices (from 66% to 74% for female, 57% to 65% for male; P < .01), and for male patients in continuity clinics (from 68% to 75%; P = .05). Series completion increased overall in community practices (39% to 43%; P = .04) and for male patients in continuity clinics (from 36% to 44%; P = .03). CONCLUSIONS: Office systems changes using a QI model and multicomponent interventions decreased rates of MO for HPV vaccination and increased initiation and completion rates among some gender subgroups. A learning collaborative model provides an effective forum for practices to improve HPV vaccine delivery.
OBJECTIVE: Human papillomavirus (HPV) vaccination rates remain low, in part because of missed opportunities (MOs) for vaccination. We used a learning collaborative quality improvement (QI) model to assess the effect of a multicomponent intervention on reducing MOs. METHODS: Study design: pre-post using a QI intervention in 33 community practices and 14 pediatric continuity clinics over 9 months to reduce MOs for HPV vaccination at all visit types. MEASURES: outcome measures comprised baseline and postproject measures of 1) MOs (primary outcome), and 2) HPV vaccine initiation and completion. Process measures comprised monthly chart audits of MOs for HPV vaccination for performance feedback, monthly Plan-Do-Study-Act surveys and pre-post surveys about office systems. INTERVENTION: providers were trained at the start of the project on offering a strong recommendation for HPV vaccination. Practices implemented provider prompts and/or standing orders and/or reminder/recall if desired, and were provided monthly feedback on MOs to assess their progress. ANALYSES: chi-square tests were used to assess changes in office practices, and logistic regression used to assess changes in MOs according to visit type and overall, as well as HPV vaccine initiation and completion. RESULTS: MOs overall decreased (from 73% to 53% in community practices and 62% to 55% in continuity clinics; P < .01, and P = .03, respectively). HPV vaccine initiation increased for both genders in community practices (from 66% to 74% for female, 57% to 65% for male; P < .01), and for male patients in continuity clinics (from 68% to 75%; P = .05). Series completion increased overall in community practices (39% to 43%; P = .04) and for male patients in continuity clinics (from 36% to 44%; P = .03). CONCLUSIONS: Office systems changes using a QI model and multicomponent interventions decreased rates of MO for HPV vaccination and increased initiation and completion rates among some gender subgroups. A learning collaborative model provides an effective forum for practices to improve HPV vaccine delivery.
Authors: Emily B Walling; Sherry Dodd; Neil Bobenhouse; Evelyn Cohen Reis; Randy Sterkel; Jane Garbutt Journal: Am J Prev Med Date: 2019-01 Impact factor: 5.043
Authors: Abdu A Adamu; Olalekan A Uthman; Elvis O Wambiya; Muktar A Gadanya; Charles S Wiysonge Journal: Hum Vaccin Immunother Date: 2019-04-22 Impact factor: 3.452
Authors: Melissa B Gilkey; Michael J Parks; Marjorie A Margolis; Annie-Laurie McRee; Jason V Terk Journal: Pediatrics Date: 2019-06-17 Impact factor: 7.124
Authors: Brigid K Grabert; Rachel Kurtzman; Jennifer Heisler-MacKinnon; Jennifer Leeman; Adam Bjork; Maddy Kameny; Amy Liu; Karen Todd; Susan Alton Dailey; Kevin Smith; Noel T Brewer; Melissa B Gilkey Journal: Transl Behav Med Date: 2022-01-18 Impact factor: 3.626
Authors: Brigid K Grabert; Jennifer Heisler-MacKinnon; Amy Liu; Marjorie A Margolis; Elizabeth D Cox; Melissa B Gilkey Journal: Hum Vaccin Immunother Date: 2021-06-21 Impact factor: 4.526